{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:02:54Z","timestamp":1792202574820,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00120-022-01854-z","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T06:03:32Z","timestamp":1655100212000},"page":"745-752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Organoide als Meilenstein auf dem Weg zur personalisierten Therapie des Urothelkarzinoms: ein systematischer Review","Organoids as a\u00a0milestone on the way to personalized treatment of urothelial carcinoma: a systematic review"],"prefix":"10.1007","volume":"61","author":[{"given":"Michael Karl","family":"Melzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Zehe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wezel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"G\u00fcnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Maisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"1854_CR1","series-title":"AWMF-Registrierungsnummer 032\/038OL","volume-title":"S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF)","year":"2020","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2020) S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0. AWMF-Registrierungsnummer 032\/038OL (https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom)"},{"key":"1854_CR2","volume-title":"Krebs in Deutschland f\u00fcr 2017\/2018","author":"Robert Koch-Institut","year":"2021","unstructured":"Robert Koch-Institut (2021) Krebs in Deutschland f\u00fcr 2017\/2018"},{"issue":"4","key":"1854_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot\u00a0Y, Necchi\u00a0A, Park\u00a0SH et\u00a0al (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N\u00a0Engl J Med 381(4):338\u2013348","journal-title":"N Engl J Med"},{"issue":"11","key":"1854_CR4","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib\u00a0L, Smith\u00a0BD, Aizenberg\u00a0R, Rosenzweig\u00a0AB, Fleshman\u00a0JM, Matrisian\u00a0LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913\u20132921","journal-title":"Cancer Res"},{"key":"1854_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13045-018-0662-9","volume":"11","author":"H Xu","year":"2018","unstructured":"Xu\u00a0H et\u00a0al (2018) Organoid technology and applications in cancer research. J\u00a0Hematol Oncol 11:116","journal-title":"J Hematol Oncol"},{"key":"1854_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"Kim\u00a0J et\u00a0al (2020) Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol 21:571\u2013584","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1854_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-4939-7234-0_12","volume":"1655","author":"T Yoshida","year":"2018","unstructured":"Yoshida\u00a0T et al (2018) Spheroid cultures of primary urothelial cancer cells: cancer tissue-originated spheroid (CTOS) method. Methods Mol Biol 1655:145\u2013153","journal-title":"Methods Mol Biol"},{"issue":"5","key":"1854_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41578-021-00279-y","volume":"6","author":"M Hofer","year":"2021","unstructured":"Hofer\u00a0M, Lutolf\u00a0MP (2021) Engineering organoids. Nat Rev Mater 6(5):402\u2013420","journal-title":"Nat Rev Mater"},{"key":"1854_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.021","author":"SF Boj","year":"2015","unstructured":"Boj\u00a0SF et\u00a0al (2015) Organoid models of human and mouse ductal pancreatic cancer. Cell. https:\/\/doi.org\/10.1016\/j.cell.2014.12.021","journal-title":"Cell"},{"key":"1854_CR10","doi-asserted-by":"publisher","first-page":"26580","DOI":"10.1073\/pnas.1911273116","volume":"116","author":"E Driehuis","year":"2019","unstructured":"Driehuis\u00a0E et\u00a0al (2019) Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci U S\u00a0A 116:26580\u201326590","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1854_CR11","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3390\/cancers13112539","volume":"13","author":"AK Beutel","year":"2021","unstructured":"Beutel\u00a0AK et\u00a0al (2021) A prospective feasibility trial to challenge patient\u2013derived pancreatic cancer organoids in predicting treatment response. Cancers (Basel) 13(11):2539","journal-title":"Cancers (Basel)"},{"key":"1854_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ADHM.202102345","author":"MK Melzer","year":"2022","unstructured":"Melzer\u00a0MK et\u00a0al (2022) Organoids at the PUB: the porcine urinary bladder serves as a\u00a0pancreatic niche for advanced cancer modeling. Adv Healthc Mater. https:\/\/doi.org\/10.1002\/ADHM.202102345","journal-title":"Adv Healthc Mater"},{"issue":"7","key":"1854_CR13","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher\u00a0D, Liberati\u00a0A, Tetzlaff\u00a0J, Altman\u00a0DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097","journal-title":"PLoS Med"},{"issue":"4","key":"1854_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.eururo.2006.10.034","volume":"51","author":"JP Burgu\u00e9s","year":"2007","unstructured":"Burgu\u00e9s\u00a0JP, G\u00f3mez\u00a0L, Pontones\u00a0JL, Vera\u00a0CD, Jim\u00e9nez-Cruz\u00a0JF, Ozonas\u00a0M (2007) A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur Urol 51(4):962\u2013969","journal-title":"Eur Urol"},{"key":"1854_CR15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1803595116","author":"J Mullenders","year":"2019","unstructured":"Mullenders\u00a0J et\u00a0al (2019) Mouse and human urothelial cancer organoids: a tool for bladder cancer research. Proc Natl Acad Sci U S\u00a0A. https:\/\/doi.org\/10.1073\/pnas.1803595116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1854_CR16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee\u00a0SH, Hu\u00a0W, Matulay\u00a0JT et al (2018) Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173(2):515\u2013528.e17","journal-title":"Cell"},{"key":"1854_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-020-3034-x","volume":"588","author":"E Kim","year":"2020","unstructured":"Kim\u00a0E et\u00a0al (2020) Creation of bladder assembloids mimicking tissue regeneration and cancer. Nature 588:664\u2013669","journal-title":"Nature"},{"issue":"18","key":"1854_CR18","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.3390\/cancers13184558","volume":"13","author":"HL Luo","year":"2021","unstructured":"Luo\u00a0HL, Liu\u00a0HY, Chang\u00a0YL, Su\u00a0YL, Huang\u00a0CC, Lin\u00a0XJ, Chuang\u00a0YC (2021) Extracorporeal shock wave enhances the cisplatin efficacy by improving tissue infiltration and cellular uptake in an upper urinary tract cancer animal and human-derived organoid model. Cancers (Basel) 13(18):4558","journal-title":"Cancers (Basel)"},{"key":"1854_CR19","doi-asserted-by":"publisher","first-page":"2103999","DOI":"10.1002\/advs.202103999","volume":"9","author":"Z Li","year":"2022","unstructured":"Li\u00a0Z et al (2022) Patient-derived upper tract urothelial carcinoma organoids as a\u00a0platform for drug screening. Adv Sci 9:2103999","journal-title":"Adv Sci"},{"issue":"1","key":"1854_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/cas.12567","volume":"106","author":"T Yoshida","year":"2015","unstructured":"Yoshida\u00a0T et al (2015) High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids. Cancer Sci 106(1):69\u201377","journal-title":"Cancer Sci"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01854-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-022-01854-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-022-01854-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:03:32Z","timestamp":1656572612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-022-01854-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1007\/s00120-022-01854-z","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"10 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.K.\u00a0Melzer, V.\u00a0Zehe, F.\u00a0Zengerling, F.\u00a0Wezel, C.\u00a0G\u00fcnes, P.\u00a0Maisch und C.\u00a0Bolenz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}